Improving and validating data-driven genotypic interpretation systems for the selection of antiretroviral therapies

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  2016-12-19

• Fields of study

  Not labeled

• Identifiers
  DOI 10.22028/D291-26681
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Practical optimization

  2019cited by this paper
• Frequentist Inference*

  2018cited by this paper
• HIV Sequence Compendium 2018

  2018influential reference
• Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

  2016cited by this paper
• Cell Viability Assays

  2016cited by this paper
• Abacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in HIV-1 Infection

  2015influential reference
• Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

  2015cited by this paper
• Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

  2015cited by this paper
• Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.

  2015cited by this paper
• Title R interface to the Levenberg-Marquardt nonlinear least-squares algorithm found in MINPACK, plus support for bounds

  2015cited by this paper
• Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access.

  2015cited by this paper
• Effects of sequence alterations on results from genotypic tropism testing.

  2015cited by this paper
• Ageing with HIV: a multidisciplinary review

  2015cited by this paper
• Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

  2015cited by this paper
• Tenofovir alafenamide: an effective option for HIV treatment with reduced risk

  2015cited by this paper
• Will drug resistance against dolutegravir in initial therapy ever occur?

  2015influential reference
• Emerging Challenges in Managing Hepatitis B in HIV Patients

  2015cited by this paper
• HIV-1 genotypic drug resistance testing: digging deep, reaching wide?

  2015cited by this paper
• Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.

  2014cited by this paper
• Current Perspectives on HIV-1 Antiretroviral Drug Resistance

  2014cited by this paper
• The Genealogical Population Dynamics of HIV-1 in a Large Transmission Chain: Bridging within and among Host Evolutionary Rates

  2014cited by this paper
• COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification

  2014influential reference
• The early spread and epidemic ignition of HIV-1 in human populations

  2014cited by this paper
• Deep sequencing of HIV: clinical and research applications.

  2014cited by this paper
• Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus.

  2014cited by this paper
• Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.

  2014cited by this paper
• Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults

  2014influential reference
• Nucleoside-Sparing Antiretroviral Regimens

  2014cited by this paper
• An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

  2014cited by this paper
• Antiviral resistance testing

  2014cited by this paper
• Who pays and why? Costs, effectiveness, and feasibility of HIV treatment as prevention.

  2014cited by this paper
• HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure

  2014cited by this paper
• Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?

  2014cited by this paper
• A comparison of computational models with and without genotyping for prediction of response to second‐line HIV therapy

  2014cited by this paper
• The Discovery and Development of Antiretroviral Agents

  2014cited by this paper
• Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

  2014cited by this paper
• Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature

  2013cited by this paper
• The Next Therapeutic Challenge in HIV: Polypharmacy

  2013cited by this paper
• Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

  2013influential reference
• Implications of HIV diversity for the HIV-1 pandemic.

  2013cited by this paper
• The origin and molecular epidemiology of HIV

  2013influential reference
• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild®): A Review of Its Use in the Management of HIV-1 Infection in Adults

  2013cited by this paper
• Phenotypic properties of transmitted founder HIV-1

  2013cited by this paper
• When to start antiretroviral therapy: as soon as possible

  2013cited by this paper
• History of blood transfusion in sub-saharan Africa.

  2013cited by this paper
• Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

  2013cited by this paper
• Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

  2013influential reference
• SOCIAL HISTORY, BIOLOGY, AND THE EMERGENCE OF HIV IN COLONIAL AFRICA*

  2013cited by this paper
• A Review of the Toxicity of HIV Medications

  2013influential reference
• Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?

  2013cited by this paper
• Modelling treatment response could reduce virological failure in different patient populations

  2013cited by this paper
• Differential genotypic evolution of HIV-1 quasispecies in cerebrospinal fluid and plasma: a systematic review.

  2013cited by this paper
• Generalized Simulated Annealing for Global Optimization: The GenSA Package

  2013cited by this paper
• Clinical implications of HIV-1 minority variants.

  2013cited by this paper
• Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV‐1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations

  2013cited by this paper
• Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools.

  2013influential reference
• Evaluation of the automatic editing tool RECall for HIV-1 pol and V3 loop sequences.

  2013cited by this paper
• Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

  2012influential reference
• HIV-1 Antiretroviral Resistance Scientific Principles and Clinical Applications

  2012cited by this paper
• The evolving epidemiology of HIV/AIDS

  2012cited by this paper
• Pill Burden in HIV Infection: 20 Years of Experience

  2012cited by this paper
• Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors

  2012cited by this paper
• Amprenavir or Fosamprenavir plus Ritonavir in HIV Infection

  2012cited by this paper
• Computational models for prediction of response to antiretroviral therapies.

  2012cited by this paper
• Enfuvirtide: A Review of its Use in the Management of HIV Infection

  2012influential reference
• The expansion of HIV-1 in colonial Léopoldville, 1950s: driven by STDs or STD control?

  2012cited by this paper
• The origin of genetic diversity in HIV-1.

  2012influential reference
• Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice.

  2012cited by this paper
• Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes

  2012cited by this paper
• Zalcitabine

  2012cited by this paper
• Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project

  2012cited by this paper
• Zidovudine

  2012cited by this paper
• Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

  2012cited by this paper
• The origin and diversity of the HIV-1 pandemic.

  2012influential reference
• Viral Quasispecies Evolution

  2012cited by this paper
• Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial

  2012cited by this paper
• Novel Approaches to Inhibit HIV Entry

  2012cited by this paper
• HIV Treatment as Prevention: Natural Experiments Highlight Limits of Antiretroviral Treatment as HIV Prevention

  2012cited by this paper
• Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.

  2012cited by this paper
• Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool

  2012cited by this paper
• On HIV diversity.

  2012cited by this paper
• HIV Type 1 Gag as a Target for Antiviral Therapy

  2012influential reference
• Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections

  2011cited by this paper
• Combinatorial Approaches to the Prevention and Treatment of HIV-1 Infection

  2011cited by this paper
• LIBSVM: A library for support vector machines

  2011influential reference
• Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach.

  2011cited by this paper
• Individualization of antiretroviral therapy

  2011cited by this paper
• Role of donor genital tract HIV-1 diversity in the transmission bottleneck

  2011cited by this paper
• Applications of Next-Generation Sequencing Technologies to Diagnostic Virology

  2011cited by this paper
• Origins of HIV and the AIDS pandemic.

  2011influential reference
• Prevention of HIV-1 infection with early antiretroviral therapy

  2011cited by this paper
• Global trends in molecular epidemiology of HIV-1 during 2000–2007

  2011cited by this paper
• HIV and aging: an overview of an emerging issue.

  2011cited by this paper
• Support vector methods for survival analysis: a comparison between ranking and regression approaches

  2011cited by this paper
• Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.

  2011cited by this paper
• Nonlinear Programming

  2010influential reference
• Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations *

  2010cited by this paper
• Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions.

  2010cited by this paper
• Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping

  2010cited by this paper
• Entry inhibitors in the treatment of HIV-1 infection.

  2010cited by this paper

• Using drug exposure for predicting drug resistance – A data-driven genotypic interpretation tool

  2017cites this paper